Female Health (Nasdaq: FHCO ) is expected to report Q4 earnings around Nov. 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Female Health's revenues will increase 33.9% and EPS will wane -35.3%.
The average estimate for revenue is $9.5 million. On the bottom line, the average EPS estimate is $0.11.
Last quarter, Female Health reported revenue of $8.7 million. GAAP reported sales were much higher than the prior-year quarter's $3.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.09. GAAP EPS of $0.09 for Q3 were much higher than the prior-year quarter's $0.01 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 61.2%, 960 basis points better than the prior-year quarter. Operating margin was 32.4%, 1,960 basis points better than the prior-year quarter. Net margin was 29.5%, 1,770 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $34.6 million. The average EPS estimate is $0.34.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 285 members out of 294 rating the stock outperform, and nine members rating it underperform. Among 55 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 55 give Female Health a green thumbs-up, and give it a red thumbs-down.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Female Health. Learn how to maximize your investment income and get "The 3 DOW Stocks Dividend Investors Need." Click here for instant access to this free report.